Chembond Chemicals Ltd Q1 FY27 Earnings Analysis

Published 31 May 2026 | Chemicals & Petrochemicals | Market Cap: ₹504 Cr

Price

185

Market Cap

₹504 Cr

P/E Ratio

15.7

Revenue Rank

Rank 3

Margin Rank

Rank 3

Earnings Summary

- The company aspires to reach ₹1000 crore in sales within four years, nearly tripling current sales (~₹330-340 crore) through geographical expansion and organic growth. - Chembond expects continued sales growth driven primarily by volume increases across all segments, especially water chemicals and construction chemicals, with volume growth estimates of 10-20%. - The company targets aspirational revenue of Rs.

📊 Revenue & Sales Performance

Rank 3

- The company aspires to reach ₹1000 crore in sales within four years, nearly tripling current sales (~₹330-340 crore) through geographical expansion and organic growth. - Volume growth is driving sales increases across businesses, with minimal impact from price increases historically. - Expected volume growth for full year: - Construction chemicals: 15-20% - Water chemicals: ~10% - New client additions and expanded presence, especially in water chemicals, are key growth drivers. - Strong order book for water chemicals and equipment signals continued growth momentum. - Construction chemicals and distribution businesses are recovering post slow periods, targeting higher sales in coming years. - Growth is expected from new product launches, technology solutions, and market penetration, especially in water treatment and construction chemicals. - EBIT margins for water chemicals are at par with industry peers, with potential to improve as scale and mix evolve.

📈 Profitability & Margins

Rank 3

- Chembond expects continued sales growth driven primarily by volume increases across all segments, especially water chemicals and construction chemicals, with volume growth estimates of 10-20%. - The company targets aspirational revenue of Rs. 1000 crore within four years, nearly tripling current sales through geographic expansion, new client acquisition, and stronger sales pipelines. - EBITDA and profit growth may face temporary margin pressure due to volatile raw material costs, but margins are expected to normalize as cost pass-through improves. - Historical experience indicates margins rebound within a few quarters post cost inflation. - Water business remains the largest segment (85-87% of sales), with intentions to grow other business lines faster to reduce water’s share. - New product innovations and integration of cleaning and hygiene with water treatment are expected to contribute incremental growth. - Overall, earnings and EPS outlook is positive, contingent on sustained industry growth and successful execution of expansion strategies.

🏗️ Capital Expenditure Plans

Yes

- No major new plant setting up or large-scale capital expenditure planned beyond the current year. - Current capital deployment focuses on network growth and geographical expansion. - FY26 capex rose to about Rs. 20-21 crores, mainly due to full-year impact of the demerger including office building renovation and allocation of property, plant & equipment. - The company is preparing for uncertain situations and focusing on readiness for various potential scenarios. - Investment in expanding presence in new segments like dairy and integration with water treatment is underway. - Emphasis on cost-competitive product development and increasing approvals from large government agencies to aid market expansion. - The company continues to scout and develop incremental technological product changes aimed at solving customer problems.

💰 Fundraising & Capital Structure

No information

- As of the current financial year, there is no plan for significant new fundraising through debt or equity. - The company has around ₹65 crores on books and intends to deploy some of it for network growth and geographical expansion. - No additional large-scale plant setting up or capital expenditure beyond the current year's CapEx is planned. - The company is preparing for worst-case scenarios and staying cautious due to the uncertain business environment. - Growth and expansion are expected to be driven organically and through selective partnerships rather than aggressive fundraising.

📋 Order Book & Pipeline

Yes

- The Water Business Unit (BU) is entering the new financial year with a **strong order book for chemicals and equipment**. - There are developments in the **bioremediation space** and an expectation to start seeing a larger contribution from the wastewater treatment subsection. - This indicates the company has a **healthy pipeline of pending orders and ongoing projects**, especially in the water chemicals sector. - Other business units like construction chemicals and cleaning & hygiene are also ramping up efforts to improve their order intake. - Overall, the outlook reflects **positive momentum in securing new orders and strong ongoing demand** in key segments.

Key Metrics

Revenue

Rank 3

Margin

Rank 3

Capex

Yes

Fundraise

No information

Order Book

Yes

Frequently Asked Questions

What were Chembond Chemicals Ltd Q1 FY27 results?

- The company aspires to reach ₹1000 crore in sales within four years, nearly tripling current sales (~₹330-340 crore) through geographical expansion and organic growth. - Chembond expects continued sales growth driven primarily by volume increases across all segments, especially water chemicals and construction chemicals, with volume growth estimates of 10-20%. - The company targets aspirational revenue of Rs.

What is Chembond Chemicals Ltd share price analysis?

Chembond Chemicals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 15.7 with a market cap of ₹504. Investors should review the full earnings analysis for detailed insights.

Is Chembond Chemicals Ltd planning capital expenditure?

- No major new plant setting up or large-scale capital expenditure planned beyond the current year. - Current capital deployment focuses on network growth and geographical expansion. - FY26 capex rose to about Rs.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.